Results for tag: "Rubraca"

Rubraca is a type of drug used to treat ovarian cancer. It is a PARP inhibitor, meaning it works by blocking an enzyme called poly ADP ribose polymerase (PARP) which helps cancer cells repair their DNA. This makes it harder for the cancer cells to survive and grow. Rubraca is used in combination with other treatments such as chemotherapy and radiation therapy. It is approved for use in patients with advanced ovarian cancer who have been previously treated with chemotherapy. Rubraca is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2016. It is currently available in the US, Canada, and Europe. It is marketed by Clovis Oncology, a biopharmaceutical company based in Boulder, Colorado. Other companies involved in the development and marketing of Rubraca include AstraZeneca, Merck, and Tesaro. Show Less Read more